Animals with a chronic infection of the parasite
Toxoplasma gondii
are protected against lethal secondary infection with other pathogens. Our group previously determined that soluble
T. gondii
antigens (STAg) can mimic this protection and be used as a treatment against several lethal pathogens. Because treatments are limited for the parasite
Cryptosporidium parvum
, we tested STAg as a
C. parvum
therapeutic. We determined that STAg treatment reduced
C. parvum
Iowa II oocyst shedding in IFNγ-KO mice. Murine intestinal sections were then sequenced to define the IFNγ independent transcriptomic response to
C. parvum
infection. Gene Ontology and transcript abundance comparisons showed host immune response and metabolism changes. Transcripts for type I interferon responsive genes were more abundant in
C. parvum
infected mice treated with STAg. Comparisons between PBS or STAg treatments showed no significant differences in
C. parvum
gene expression.
C. parvum
transcript abundance was highest in the ileum and mucin-like glycoproteins and the GDP-fucose transporter were among the most abundant. These results will assist the field in determining both host- and parasite-directed future therapeutic targets.